Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Li

Showing results (141-150 of 206) with videos related to

Pageof 21
Sort By:
The Journal of Urology|May 25, 2021
Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder CancerNicholas H Chakiryan, Da David Jiang, Kyle A Gillis, et al.
BJU International|November 1, 2024
A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomyJoep J de Jong, James A Proudfoot, Siamak Daneshmand, et al.
European Urology Open Science|February 12, 2025
Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical CystectomyJoep J de Jong, James A Proudfoot, Siamak Daneshmand, et al.
European Urology|October 1, 2024
FGFR Inhibition in Urothelial CarcinomaRoger Li, Joshua Linscott, James W F Catto, et al.
Urology|August 23, 2025
Smoking is Associated with Poorer Survival Outcomes Following Nephroureterectomy for Upper Tract Urothelial CancerKelly Lehner, Roger Li, Patrick J Hensley, et al.
The Oncologist|March 23, 2026
Homologous Recombination Deficiency and Genomic Alterations in Advanced Prostate Cancer: Insights for Precision TherapyChiara Mercinelli, Dean Pavlick, Neeraj Agarwal, et al.
The Journal of Urology|September 25, 2019
The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient DataEsmée I M L Liem, Jorg R Oddens, Robin W M Vernooij, et al.
Current Oncology Reports|June 5, 2024
From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder CancerJoshua A Linscott, Hiroko Miyagi, Prithvi B Murthy, et al.
Breast Cancer Research and Treatment|January 11, 2015
Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family RegistryTú Nguyen-Dumont, Fleur Hammet, Maryam Mahmoodi, et al.
Clinical and Translational Medicine|March 10, 2026
Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapyNils C H van Creij, Piotr Tymoszuk, Florian Handle, et al.
Pageof 21

Showing results (141-150 of 206) with videos related to

Sort By:
Pageof 21
The Journal of Urology|May 25, 2021
Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder CancerNicholas H Chakiryan, Da David Jiang, Kyle A Gillis, et al.
BJU International|November 1, 2024
A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomyJoep J de Jong, James A Proudfoot, Siamak Daneshmand, et al.
European Urology Open Science|February 12, 2025
Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical CystectomyJoep J de Jong, James A Proudfoot, Siamak Daneshmand, et al.
European Urology|October 1, 2024
FGFR Inhibition in Urothelial CarcinomaRoger Li, Joshua Linscott, James W F Catto, et al.
Urology|August 23, 2025
Smoking is Associated with Poorer Survival Outcomes Following Nephroureterectomy for Upper Tract Urothelial CancerKelly Lehner, Roger Li, Patrick J Hensley, et al.
The Oncologist|March 23, 2026
Homologous Recombination Deficiency and Genomic Alterations in Advanced Prostate Cancer: Insights for Precision TherapyChiara Mercinelli, Dean Pavlick, Neeraj Agarwal, et al.
The Journal of Urology|September 25, 2019
The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient DataEsmée I M L Liem, Jorg R Oddens, Robin W M Vernooij, et al.
Current Oncology Reports|June 5, 2024
From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder CancerJoshua A Linscott, Hiroko Miyagi, Prithvi B Murthy, et al.
Breast Cancer Research and Treatment|January 11, 2015
Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family RegistryTú Nguyen-Dumont, Fleur Hammet, Maryam Mahmoodi, et al.
Clinical and Translational Medicine|March 10, 2026
Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapyNils C H van Creij, Piotr Tymoszuk, Florian Handle, et al.
Pageof 21